Home Sectors Healthcare Stock Under Review: Catalent (NYSE: CTLT)

Stock Under Review: Catalent (NYSE: CTLT)


Catalent trades as part of the healthcare sector and drug manufacturers industry. The company CEO is John R. Chiminski. Catalent Inc is a drug development, delivery and supply partner company. It engages in advanced delivery technologies and development solutions for drugs, biologics, and consumer health products across US, Europe and other international markets.

Previous Intraday Trading Performance:

The CTLT stock showed a previous change of 2.61% with an open at 46.13 and a close of 46.78. It reached an intraday high of 46.83 and a low of 45.90.

SeekingAlpha:  Daily Insider Ratings Roundup 5/30/19


The stock has a market cap of $6.8b with 145.7m shares outstanding, of which the float is 144.7m shares. Trading volume reached 697,799 shares compared to its average volume of 769,772 shares. Based on the current average volume and close price, the trading liquidity is good.

Historical Trading Performance:

Over the last five trading days, Catalent shares returned 3.06% and in the past 30 trading days it returned 5.24%. Over three months, it changed 7.02%. In one year it has changed 19.06% and within that year its 52-week high was 47.04 and its 52-week low was 29.23. CTLT stock is 60.04% above its 52 Week Low.

Our calculations show a 200 day moving average of 40.56 and a 50 day moving average of 43.51. Currently CTLT stock is trading 15.32% above its 200 day moving average.

SeekingAlpha:  Daily Insider Ratings Roundup 5/30/19


The last annual fiscal EPS for the company was reported at 0.63 that ended on 30th of June 2018, which according to the previous close, that is a PE of 74.25. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.24. The TTM EPS is 1.64, which comes to a TTM PE of 28.52.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/07/2019): 0.22
4thQtr of 2018 (Reported on 02/05/2019): 0.33
3rdQtr of 2018 (Reported on 11/06/2018): -0.10
2ndQtr of 2018 (Reported on 08/28/2018): 0.61
1stQtr of 2018 (Reported on 05/01/2018): 0.14

Base on our calculations, the intrinsic value per share is 61.87, which means it is possibly undervalued and has a margin of safety of 24.39%.

Indicators to Watch:

Short-interest was 4,270,369, which was 2.93% of shares outstanding. The short-interest ratio or days-to-cover ratio was 6.01. This stock has some short interest, but it may be normal and no cause for concern if long the position.

The current calculated beta is 1.57.

SeekingAlpha:  Douglas Emmett reports Q1 results

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 11.49%, return on assets is 3.45%, profit margin is 6.00%, price-to-sales is 2.68 and price-to-book is 4.10.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 3  :Past Performance Score
 2  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.